Association between clinical specialty setting and disease management in patients with psoriatic arthritis: Results from LOOP, a cross-sectional, multi-country, observational study

Autor: F. Ganz, Ediz Dalkilic, S.A.L. Lima, R. Horváth, Wolf-Henning Boehncke, M. Okada, Ennio Lubrano, M. Hojnik
Přispěvatelé: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı., CMF-4757-2022, Dalkılıç, Ediz
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Cross-sectional study
Recommendations
urologic and male genital diseases
Observational study
Disease management
Prevalence
Medicine
Europe
Eastern
Disease activity
Disease management (health)
Disease course
skin and connective tissue diseases
Arthritis
Psoriatic/diagnosis
Priority journal
ddc:616
Delay
food and beverages
Disease Management
Pustulosis Palmoplantaris
Secukinumab
Nail Diseases
Disease burden
Disease modifying antirheumatic drug
Multicenter study
Infectious Diseases
Psoriatic arthritis
Cross-sectional studies
Female
Musculoskeletal system inflammation
Dermatologist
Rheumatologist
Human
Adult
medicine.medical_specialty
Asia
Specialty
Western Europe
Arthritis
Psoriatic/drug therapy
Dermatology
Eastern Europe
Major clinical study
Patient care
Article
South and Central America
Arthritis
psoriatic
Middle East
Age
Rheumatology
Psoriasis
Internal medicine
Humans
Medical specialist
Time to treatment
business.industry
fungi
medicine.disease
Cross-Sectional Studies
business
Zdroj: Journal of the European Academy of Dermatology and Venereology, Vol. 34, No 9 (2020) pp. 2035-2043
ISSN: 0926-9959
Popis: Background Psoriatic arthritis (PsA) is a chronic and debilitating disease that can be managed by different clinical specialists. Objectives The objective of theLOOPstudy was to evaluate the impact of clinical specialty setting on the time to diagnosis and treatment of patients with PsA. Clinical disease activity and disease burden were also compared between clinical settings. Methods LOOPwas a cross-sectional, multicentre, observational study conducted in 17 countries in Western and Eastern Europe, the Middle East, Latin America and Asia. Adult patients (>= 18 years) with a suspected or established diagnosis of PsA who were routinely visiting a rheumatologist, dermatologist or non-rheumatology/non-dermatology physician were enrolled. All patients were assessed by both a rheumatologist and a dermatologist. Results Of 1483 enrolled patients, a total of 1273 had a confirmed diagnosis of PsA. There was no significant difference in the median time from onset of inflammatory musculoskeletal symptoms to PsA diagnosis between patients enrolled by rheumatologists and dermatologists (6.0 vs. 3.9 months). However, the median time from diagnosis to first treatment with a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) was significantly shorter in the rheumatology setting compared with the dermatology setting (0 vs. 2.0 months;P < 0.001). In addition, disease activity was significantly higher in the dermatology setting compared with the rheumatology setting. Conclusions Differences in the management and clinical status of patients with PsA were observed between the rheumatology and dermatology settings. Importantly, median time from diagnosis to first csDMARDwas significantly shorter in the rheumatology setting, and patients in the dermatology setting had higher disease activity. These data show the importance of improved collaboration between rheumatologists and dermatologists. AbbVie
Databáze: OpenAIRE
Externí odkaz: